Join the Eye Conditions group to help and get support from people like you.
Eye Conditions News (Page 5)
Related terms: Eye Disorders
FDA Medwatch Alert: Gericare Eye Wash by Kareway Products: Recall - Potential Product Contamination
[Posted 02/02/2018] ISSUE: Kareway Products, Inc is voluntarily recalling 60,000 lots of Gericare Eye Wash, Sterile Eye Irrigation Solution, 4 fluid ounces to the hospital, retail or consumer level....
Bausch + Lomb Receives FDA Approval of Lumify (brimonidine tartrate) Over-the-Counter Eye Drop for the Treatment of Eye Redness
LAVAL, Quebec, Dec. 22, 2017 /PRNewswire/ – Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX)...
FDA Approves Genentech’s Lucentis (ranibizumab) for Myopic Choroidal Neovascularization
South San Francisco, CA – January 5, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved...
FDA Medwatch Alert: Family Care Eye Wash by United Exchange Corp: Recall - Microbial Contamination
[Posted 09/08/2016] ISSUE: United Exchange Corp. is voluntarily recalling specific lots of Family Care Eye Wash 4 oz due to microbial contamination. These products consist of a purified water ...
FDA Medwatch Alert: Eye Wash/Eye Irrigating Solutions Distributed by Major Pharmaceuticals and Rugby Laboratories: Recall - Microbial Contamination
ISSUE: United Exchange Corp. of Cerritos, CA, a primary source vendor of the Rugby-branded Eye Irrigating Solution and Major-branded Eye Wash, is voluntarily recalling products due to microbial...
FDA Medwatch Alert: Refresh Lacri-Lube, Refresh P.M., FML 0.1 Percent and Blephamide 10 Percent/0.2 Percent by Allergan: Recall - Particulate Matter
ISSUE: Allergan announced that it is conducting a voluntary recall down to consumer level of specific lots of its Refresh Lacri-Lube 3.5g and 7g for dry eye, Refresh PM 3.5g for dry eye, FML...
FDA Approves Hetlioz: First Treatment for Non-24 Hour Sleep-Wake Disorder in Blind Individuals
January 31, 2014 – The U.S. Food and Drug Administration today approved Hetlioz (tasimelteon), a melatonin receptor agonist, to treat non-24- hour sleep-wake disorder (“non-24”) in totally blind ind...
FDA Approves Jetrea for Symptomatic Vitreomacular Adhesion in the Eyes
October 18, 2012 – On Oct. 17, the U.S. Food and Drug Administration approved Jetrea (ocriplasmin), the first drug approved to treat an eye condition called symptomatic vitreomacular adhesion (VMA)....
Sigma-Tau Pharmaceuticals, Inc. Receives FDA Approval of Cystaran (cysteamine ophthalmic solution) 0.44%
GAITHERSBURG, MD, October 04, 2012 —Sigma-Tau Pharmaceuticals, Inc. announced today that the Company has received approval from the U.S. Food & Drug Administration (FDA) for Cystaran (cysteamine o...
Further information
Related condition support groups
Glaucoma, Eye Dryness / Redness, Macular Degeneration, Cataract, Macular Edema